Lotte Biologics Participates in World's Largest Pharma and Bio Expo 'CPhI 2023'

Lotte Biologics announced on the 24th that it will participate in the 'International Pharmaceutical Exhibition (CPhI Worldwide 2023)', the world's largest pharmaceutical and bio expo held over three days from the 24th to the 26th (local time) in Barcelona, Spain.

Lotte Biologics' promotional booth installed at the 'International Pharmaceutical Exhibition (CPhI WorldWide 2023)' held in Barcelona, Spain.
[Photo by Lotte Biologics]

First launched in 1990, CPhI is held annually in major cities around the world. It offers exhibitions, seminars, and various side events, contributing to the advancement of the global pharmaceutical and bio industries. This year's event focuses on sustainability, implementing various policies to reduce environmental impact, including ▲100% use of renewable energy ▲minimizing single-use exhibition booths (Better Stands Program) ▲minimizing single-use plastic usage.

Following last year, Lotte Biologics is participating again with a solo booth and has created the booth using reusable eco-friendly materials such as metal frames, light panels, and digital signage to align with the event’s 'sustainability' theme. Through this, the company plans to emphasize its eco-friendly initiatives to potential clients and introduce its differentiated competitiveness, including the production capacity of its U.S. Syracuse plant, plans to establish an antibody-drug conjugate (ADC) technology platform, mid-to-long-term business strategies through its domestic bio plant, and the establishment of a Bio-Venture Initiative. In particular, it highlights the distinction of separately designing eight 3000ℓ stainless steel bioreactors within the first plant of the domestic bio plant to meet the demand for high-titer antibody drugs, signaling an expansion of the range of services the company offers.

Additionally, to facilitate smooth meetings with various institutions such as major global pharmaceutical companies and small to mid-sized biotech firms both domestic and abroad, pre-arranged meeting tables and two private meeting rooms have been set up inside the booth.

A bird's-eye view of Lotte Biologics' bio plant in Songdo, Incheon.
[Photo by Lotte Biologics]

Kim Kyung-eun, Head of Business Development at Lotte Biologics, stated, “Since announcing the construction of a 360,000ℓ bio plant in Songdo International City, Incheon, inquiries regarding completion schedules and production capacity have continued from potential clients.” She added, “Based on the synergy between the already acquired U.S. Syracuse plant and the upcoming Songdo bio plant, we will actively expand our contract development and manufacturing organization (CDMO) business.”

This content was produced with the assistance of AI translation services.